Nexium Capsules RE Maintenance Specific Clinical Experience Investigation
Overview
The purpose of this study is to collect following data in patients given Nexium capsule (Nexium) in usual post-marketing use as the maintenance therapy for repeatedly recurring/relapsing reflux oesophagitis.
Full Title of Study: “Nexium Capsules Specific Clinical Experience Investigation for Maintenance Therapy for Repeatedly Recurring/Relapsing Reflux Oesophagitis”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: July 2014
Detailed Description
Nexium capsules Specific Clinical Experience Investigation for Maintenance Therapy for Repeatedly Recurring/Relapsing Reflux Oesophagitis
Arms, Groups and Cohorts
- Nexium
Clinical Trial Outcome Measures
Primary Measures
- Number of Adverse Drug Reactions
- Time Frame: 6 Month
- Adverse event incidence
Secondary Measures
- Non-recurrence rate of reflux oesophagitis
- Time Frame: 6 Month
Participating in This Clinical Trial
Inclusion Criteria
- Patients with repeatedly recurring/relapsing reflux oesophagitis who will be given Nexium for the first time as a maintenance therapy. Exclusion Criteria:
- Patients having reflux oesophagitis when Nexium is started (Grade A, Grade B, Grade C or Grade D of Los Angeles Classification (Hoshihara's modification) on endoscopy) – Patients having previous history of maintenance therapy for repeatedly recurring/ relapsing reflux oesophagitis
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- AstraZeneca
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Shigeru Yoshida, MD, Study Director, AstraZeneca K.K.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.